Biologics

Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus

KALAMAZOO, Mich., Feb. 1, 2011 /PRNewswire/ — Stryker Corporation (NYSE: SYK) announced today the closing of the previously announced sale of its OP-1 product family, which includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft, for use in orthopaedic bone applications. The transaction also includes the sale of the manufacturing facility in Lebanon, NH.

Stryker is one of the world’s leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care.   The Company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives.  For more information about Stryker, please visit www.stryker.com.

SOURCE Stryker Corporation

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button